On Wednesday, TG Therapeutics (TGTX) got an upgrade to its Relative Strength (RS) Rating, from 76 to 81.

周三，TG Therapeutics（TGTX）将其相对强度（RS）评级从76提升至81。

X

十

IBD's unique rating tracks price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.

IBD的独特评级以1（最差）到99（最佳）的分数跟踪价格走势。该分数显示了过去52周内一只股票的价格走势与我们数据库中所有其他股票的比较。

Over 100 years of market history shows that the best stocks typically have an 80 or better RS Rating in the early stages of their moves.

100多年的市场历史表明，最好的股票在其走势的早期阶段通常具有80或更高的RS评级。

Hone Your Stock-Picking Skills By Focusing On These Factors

通过关注这些因素来磨练你的选股技能

TG Therapeutics is not currently showing a potential buy point. See if the stock goes on to build a promising consolidation that could launch a new move.

TG Therapeutics目前尚未显示出潜在的购买点。看看该股是否会继续进行有希望的合并，从而启动新的举措。

TG Therapeutics posted 0% earnings growth in its most recent report, while sales growth came in at 714%.

TG Therapeutics在其最近的报告中公布了0%的收益增长，而销售额增长为714%。

TG Therapeutics holds the No. 35 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics (HALO), United Therapeutics (UTHR) and Vertex Pharmaceuticals (VRTX) are among the top 5 highly rated stocks within the group.

TG Therapeutics在医疗生物医学/生物技术产业集团的同行中排名第35位。Halozyme Therapeutics（HALO）、United Therapeutics（UTHR）和Vertex Pharmaceuticals（VRTX）是该集团排名前五的高评级股票。

RELATED:

相关：

Biotech And Pharmaceutical Industry And Stock News

生物技术和制药行业及股票新闻

IBD Stock Rating Upgrades: Rising Relative Strength

IBD股票评级升级：相对实力上升

Why Should You Use IBD's Relative Strength Rating?

为什么要使用IBD的相对强度评级？

How Relative Strength Line Can Help You Judge A Stock

相对优势线如何帮助你判断一只股票

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

准备好提高你的投资技能了吗？加入IBD Meetup小组！